title: Anal squamous cell carcinoma in HIV/AIDS patients in the HAART era: Report of 8 cases and literature review.
abstract: BACKGROUND
  Anal squamous cell carcinoma is a rare neoplasm with a higher incidence in the HIV-seropositive population.
  
  
  METHODS
  Epidemiologic, clinic, immunologic, virologic and therapeutic characteristics of 8 HIV-positive patients with anal squamous cell carcinoma were descriptively and retrospectively analyzed from 2005 to 2011.
  
  
  RESULTS
  Median of age ofpatients was 39 years, 75% were male and 83% were men who have sex with men. Median elapsed time from HIV infection to anal cancer diagnosis was 10.5 ± 9.5 years. Anal pain and local large tumors detected by physical examination were the most common clinical manifestations; pain with or without itching was marginally correlated with poor survival. The median of CD4 T-cell countfor the whole study group was 330 cells/µL. At the time ofthe neoplasm diagnosis, CD4 T-cell count was more than 200 cell/µL in 62.5% of the patients. In the descriptive analysis, higher CD4 T-cell count was significantly associated with a prolonged survival. In the overall population, 71% were receiving highly active antiretroviral therapy (HAART) and all of them had undetectable viral load at the time ofneoplasm diagnosis. HAART was correlated with better survival in the overallpopulation. Histopathologic examination showed that 4 cases (50%) had in situ carcinoma and 4 patients (50%) had diagnosis of invasive anal carcinoma. One patient underwent surgical tumorectomy plus HAART, 2 patients received chemotherapy plus HAART and 3 patients were treated with fractionated radiotherapy plus systemic chemotherapy plus HAART. One patient died without the possibility of treatment due to his poor clinical condition and for one patient was no available data. After a follow up of 2 years, overall survival rate was 71%.
  
  
  CONCLUSIONS
  A carefully evaluation of anal infiltrative or tumoral lesions is necessary to achieve an early diagnosis and to improve the survival in this kind of patients.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Corti
authors.forename: María F
authors.initials: MF
authors.lastname: Villafañe
authors.forename: María M
authors.initials: MM
authors.lastname: Priarone
authors.forename: Natalia
authors.initials: N
authors.lastname: Vittar
authors.forename: Daniel
authors.initials: D
authors.lastname: Lewi
authors.forename: Esteban
authors.initials: E
authors.lastname: Marona
authors.forename: Leonardo
authors.initials: L
authors.lastname: Gilardi
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001005:Anus Neoplasms / Q000276:immunology / Q000401:mortality / Q000821:virology*; D018791:CD4 Lymphocyte Count; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000401:mortality / Q000821:virology*; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D019562:Viral Load